AbbVie Inc.
AbbVie Announces Preliminary Q1 2025 Financial Results and Adjusts Guidance
Summary
AbbVie Inc. reported preliminary unaudited financial results for the first quarter of 2025, which included an acquired IPR&D and milestones expense of $248 million, resulting in an unfavorable impact of $0.13 to both GAAP and adjusted non-GAAP diluted earnings per share. This expense has led to the adjustment of AbbVie's full-year 2025 adjusted diluted earnings per share guidance to a range of $11.99 to $12.19, and the first quarter guidance to a range of $2.34 to $2.38. These adjustments exclude the impact of the licensing agreement with Gubra for GUB014295, which closed after the first quarter. Detailed financial guidance, including the impact of the acquired IPR&D and milestones expense, is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Profitelligence Alerts
Get alerts for ABBV
Be first to know when AbbVie Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Official SEC Documents
Advertisement